CFA
NVAX icon

Camarda Financial Advisors’s Novavax NVAX Stock Holding History

Camarda Financial Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-5
Closed -$1K – 241
2016
Q2 		$1K Buy
+5
New +$573 ﹤0.01% 252

Other funds holding NVAX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Camarda Financial Advisors's NVAX Position: Q3 2016 in Review

Camarda Financial Advisors sold out of Novavax (NVAX) in Q3 2016, closing a stake of 5 shares — an estimated $1K sold.

Camarda Financial Advisors first reported a position in NVAX in Q2 2016 and held it in 1 quarter. The position peaked at $1K in Q2 2016. 165 funds tracked by Wall St. Rank hold NVAX as of Q3 2016.

  • Camarda Financial Advisors reported no remaining Novavax position as of Q3 2016 after selling out during the quarter.
  • Camarda Financial Advisors sold 5 Novavax shares in Q3 2016, an estimated $1K.
  • Camarda Financial Advisors first reported a position in Novavax in Q2 2016 and held it in 1 quarter.
  • Camarda Financial Advisors's Novavax position peaked at $1K in Q2 2016.
  • 165 funds tracked by Wall St. Rank held Novavax as of Q3 2016.

Based on Camarda Financial Advisors's 13F filing for Q3 2016, filed 10 Nov 2016.